PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Anthem BCBSCommercial · Prior Auth · Pharmacy · NY · Oncology, Hematology, PharmacyHigh impact

[New York] Specialty pharmacy updates

Act
by Dec 31, 2026
Effective date
Jan 1, 2027
Identified
Sep 26, 2026

Summary

Anthem Blue Cross and Blue Shield in New York is implementing new prior authorization requirements for three specialty oncology medications (Avgemsi, Docivyx, Beizray) effective January 1, 2027. Additionally, step therapy requirements are being applied to pemetrexed, bendamustine, and docetaxel products, with specific formulations designated as preferred or non-preferred, requiring step therapy protocols before dispensing non-preferred agents.

Get alerts when payers change rules like this one

We check Anthem BCBS and other payers every day and email you when a change matches your specialty and state.

Get Anthem BCBS alertsPolicy Monitoring is free. No card required.

What to do

by Dec 31, 2026 · 5 steps
01Billing team and oncology providers must implement prior authorization protocols for gemcitabine (Avgemsi, J9184), docetaxel (Docivyx J9172, Beizray J9174) when treating New York commercial members.
02Update billing software and clinical documentation templates to require prior auth submission through Carelon Medical Benefits Management for these three medications.
03Simultaneously, update step therapy workflows to enforce preferred/non-preferred designations for pemetrexed (J9305, J9294, J9296, J9297, J9314, J9322, J9323, J9304, J9324, J9292), bendamustine (J9033, J9034, J9036, J9056), and docetaxel (J9171, J9232, J9172, J9174) products—non-preferred formulations (Pemrydi RTU, Axtle, Belrapzo, Vivimusta, Docivyx, Beizray) require step therapy completion before dispensing.
04Train providers to document medical necessity for all specialty pharmacy requests.
05Claims submitted without required prior authorization or step therapy completion will be denied for dates of service on or after January 1, 2027.

Codes mentioned

J9184J9172J9174J9305J9294J9296J9297J9314J9322J9323J9304J9324J9292J9033J9034J9036J9056J9201J9196J9232

Original notice

[New York] Specialty pharmacy updates
providernews.anthem.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account